Search bioRxiv⌕ Search

Biology subjects

Nonell, L.

Publications and source records attributed to Nonell, L..

7 recordsLinked to original sources

Integrating trajectory inference and gene regulatory network analysis to resolve transcriptional programs of T cell state transitions in the tumor microenvironment

Reconstructing dynamic immune cell state transitions from single-cell transcriptomic data requires coordinated analytical strategies that capture both phenotypic progression and underlying regulatory programs. This protocol describes a step-by-step computational workflow for analyzing human tumor-infiltrating T cells using the sequential application of dimensionality reduction, pseudotime trajectory inference, regulon activity analysis, and transcription factor-transcription factor network reconstruction. The workflow outlines data preprocessing and quality control, trajectory rooting and parameter selection, branch-specific differential analysis, and the integration of regulon inference to contextualize transcriptional programs along inferred trajectories. Regulon-based TF-TF network reconstruction is used as a downstream interpretive layer to identify regulatory modules associated with distinct cell-state transitions. Publicly available at GitHub repository https://github.com/rogercasalsfr/immuno-trajectory-grn-integrative-workflow, this protocol emphasizes practical considerations including parameter sensitivity, trajectory robustness, and consistency between phenotypic and regulatory outputs. The protocol supports reproducible analysis and interpretation of immune cell dynamics in human tumor microenvironment studies using single-cell RNA sequencing data.

bioinformatics↗

Transcriptional reprogramming of tumor-infiltrating T cells during PD-1 blockade revealed through gene regulatory network and trajectory inference in squamous cell carcinoma

Understanding the tumor microenvironment is crucial for optimizing anti-cancer immune responses. At single-cell resolution, trajectory inference methods can reconstruct the dynamic transitions between cell states during differentiation. Immune checkpoint blockade (ICB) therapies, such as PD-1/PD-L1 inhibitors, are used across multiple cancers, including non-melanoma skin cancers (NMSCs), yet the transcriptional mechanisms that shape T cell responses in this context remain unclear. Here, we analyzed a publicly available squamous cell carcinoma (SCC) single-cell RNA-seq dataset comprising 25,581 tumor-infiltrating T-cell profiles to map differentiation trajectories before and after anti-PD-1 therapy. In CD8+ T cells, therapy enhanced the transition from memory to activated states, prominently involving IL-12-associated pathways, and revealed a distinct memory-to-exhaustion trajectory driven by EOMES and TCF7 regulatory activity. Gene regulatory network inference further revealed therapy-induced transcriptional rewiring distinguishing precursor exhausted (Tpex) from terminally exhausted (Tex) states. CD4+ T cell populations also underwent substantial reshaping, with trajectory and functional analyses highlighting therapy-driven programs that enhanced CXCL13+ Tfh responses while generating fewer but more transcriptionally active Tregs. Together, these findings reveal a dual remodeling of helper and cytotoxic T cell compartments upon PD-1 blockade, define key transcriptional regulators controlling cell-state transitions, and identify potential molecular targets and biomarkers to predict and enhance treatment response.

immunology↗

EWS-FLI1 Expression in Human Embryonic MSCs Leads to Transcriptional Reprograming, Defective DNA Damage Repair and Ewing Sarcoma

Ewing sarcoma (ES) is an aggressive bone and soft tissue neoplasm characterized by EWSR1/ETS rearrangements and whose cellular origin remains unclear. EWS-FLI1 expression in human pediatric mesenchymal stem cells (hpMSCs) induces a quantitatively and qualitatively different transcriptional response than its expression in human adult MSCs (haMSCs), but fails to form tumors in vivo. ES cells have early developmental lineage signatures distinct from postnatal MSCs. Here, we have generated MSCs from experimental teratomas out of human embryonic stem cells (heSCs). Transduction of these human embryonic mesenchymal stem cells (heMSCs) with EWS-FLI1 results in the acquisition of an ES transcriptome, although the oncogene does not preferentially bind to promoters, but to intronic and intergenic microsatellites with >10 CA dinucleotides and GGAA repeats, respectively. In heMSCs, EWS-FLI1 directly regulates BRCA1 expression, although EWS-FLI1-expressing cells show defects in DNA damage repair. Xenografting of EWS-FLI1-transduced heMSCs resulted in the formation of tumors expressing characteristic ES markers. In summary, EWS-FLI1 enforces an aberrant transcriptome and endows in vivo transforming capacity when expressed in an undifferentiated early heMSC. Our approach represents an innovative experimental method for understanding critical aspects of the biology of developmental tumors, from leukemia to sarcomas, in which few (even single) genetic alterations are able to transform a fetal stem cell.

cancer biology↗

Evaluation of homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays

PurposeMetastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations; these biomarkers have prognostic and predictive value. Next-generation sequencing (NGS) allows for patient stratification based on these biomarkers, but widespread clinical implementation is still limited. Moreover, not all mutations in HRR genes result in functional HRR loss in the tumor. We investigated the correlation between genomic and functional loss of HRR, using NGS and an optimized RAD51 immunofluorescence (RAD51-IF) assay in mPC clinical biopsies. Experimental designObservational study including patients with stage IV prostate cancer. Biopsies from either primary tumor or metastatic biopsies underwent NGS (targeted sequencing and/or whole-exome sequencing), and RAD51-IF. Clinical data was extracted from electronic patient records. Results219 biopsies from 187 patients were acquired, including primary (151/219) and metastatic (68/219) tumor biopsies collected either in the metastatic hormone- sensitive (169/219) or castration-resistant (50/219) setting. NGS (181 biopsies from 157 patients) showed frequent genomic alterations in TP53 (40%), AR (15%), PTEN (14%), MYC (10%), BRCA2 (9%), ATM (8%) and BRCA1 (2%). Tissue for RAD51 IF was available for 206 samples; of those, 140/206 (68%) were evaluable for RAD51- IF. Based on a previously defined threshold of 10% RAD51-positive cells, 21% samples had RAD51-low results compatible with HRR deficiency (HRD). Sample matched RAD51-IF and genomics data were obtained for 128 biopsies (117 patients): RAD51-IF had a high sensitivity (68%) and specificity (85%) to identify cases with BRCA1/2 alterations. Additionally, the RAD51-IF assay was able to identify restoration of HRR function in selected cases with BRCA2 reversion mutations or BRCA1 expression. ConclusionsRAD51-IF is feasible in routine clinical samples from mPC patients and associates strongly with clinically relevant HRR gene alterations.

cancer biology↗

Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution

Extracellular vesicles (EVs) secreted by tumors are abundant in plasma, but their potential for interrogating the molecular features of tumors through multi-omic profiling remains widely unexplored. Genomic and transcriptomic profiling of circulating EV-DNA and EV-RNA isolated from a range of in-vitro and in-vivo models of metastatic prostate cancer (mPC) revealed a high contribution of tumor material to EV-loaded DNA/RNA. Findings were validated in a cohort of longitudinal plasma samples collected from mPC patients during androgen receptor signaling inhibitor (ARSI) therapy. EV-DNA genomic features recapitulated matched-patient biopsies and associated with clinical progression. We developed a novel approach to enable the transcriptomic profiling of EV-RNA (RExCuE). We report how the transcriptomic profile in mPC EV-RNA is enriched for tumor-associated transcripts when compared to same patient blood RNA and healthy individuals EV-RNA, and reflect early on-therapy tumor adaptation changes. Altogether, we show that EV profiling enables longitudinal transcriptomic and genomic profiling of mPC in liquid biopsy.

cancer biology↗

Behavioural and transcriptomic characterization of the comorbidity between Alzheimer s disease and Major Depression

Major Depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimers disease (AD). Despite both diseases having a robust genetic component, the common transcriptomic signature remains unknown. In this regard, we investigated the cognitive and emotional responses in 3- and 6-month-old in APP/PSEN1-Tg mutant mice, before {beta}-amyloid plaques were detected. Then, we studied the deregulation of genes and pathways in prefrontal cortex, striatum, hippocampus and amygdala, using transcriptomic and functional data analysis. The results demonstrated that depressive-like and anxiety-like behaviours, as well as memory impairments are already present at 3-month-old together with the deregulation of several genes and gene sets, including components of the circadian rhythms, electronic transport chain and neurotransmission. Finally, DisGeNET GSEA provides translational support for common depregulated gene sets related to MD and AD. Altogether, the results demonstrate that MD could be an early manifestation of AD.

neuroscience↗

Are methylation beta-values simplex distributed?

DNA methylation plays an important role in the development and progression of disease. Beta-values are the standard methylation measures. Different statistical methods have been proposed to assess differences in methylation between conditions. However, most of them do not completely account for the distribution of beta-values. The simplex distribution can accommodate beta-values data. We hypothesize that simplex is a quite flexible distribution which is able to model methylation data.\n\nTo test our hypothesis, we conducted several analyses using four real data sets obtained from microarrays and sequencing technologies. Standard data distributions were studied and modelled in comparison to the simplex. Besides, some simulations were conducted in different scenarios encompassing several distribution assumptions, regression models and sample sizes. Finally, we compared DNA methylation between females and males in order to benchmark the assessed methodologies under different scenarios.\n\nAccording to the results obtained by the simulations and real data analyses, DNA methylation data are concordant with the simplex distribution in many situations. Simplex regression models work well in small sample size data sets. However, when sample size increases, other models such as the beta regression or even the linear regression can be employed to assess group comparisons and obtain unbiased results. Based on these results, we can provide some practical recommendations when analyzing methylation data: 1) use data sets of at least 10 samples per studied condition for microarray data sets or 30 in NGS data sets, 2) apply a simplex or beta regression model for microarray data, 3) apply a linear model in any other case.

bioinformatics↗